Valuation : Pulmonx Corporation

Market Cap 107M 92.16M 86.5M 79M 149M 10.24B 150M 1.02B 397M 5.17B 403M 394M 17.11B P/E 2026 *
-2.39x
P/E 2027 * -2.65x
Enterprise Value 107M 92.16M 86.5M 79M 149M 10.24B 150M 1.02B 397M 5.17B 403M 394M 17.11B EV / Sales 2026 *
1.19x
EV / Sales 2027 * 1.09x
Free-Float
95.2%
Yield 2026 *
-
Yield 2027 * -
1 day+2.00%
1 week+10.22%
Current month+55.52%
1 month+107.79%
3 months+64.61%
6 months+60.44%
Current year+14.71%
1 week 2.2
Extreme 2.195
2.59
1 month 1.22
Extreme 1.22
2.59
Current year 1.13
Extreme 1.13
2.59
1 year 1.13
Extreme 1.13
2.89
3 years 1.13
Extreme 1.13
14.84
5 years 1.13
Extreme 1.13
45.49
10 years 1.13
Extreme 1.13
69.48
Manager TitleAgeSince
Chief Executive Officer 64 27/10/2025
Director of Finance/CFO 53 01/05/2019
Chief Tech/Sci/R&D Officer - 01/03/2020
Director TitleAgeSince
Director/Board Member 72 01/02/2007
Chairman 66 01/10/2019
Director/Board Member 64 18/12/2014
Date Insider Type Main position Quantity % Market Cap.
02/03/26 Sell

Executive/Senior Manager

107,732 0.2612%
08/12/25 Sell

Director

23,321 0.0565%
03/12/25 Other

Chief Technology Officer

358,426 0.8690%
Change 5-day change 1-year change 3-year change Capi.($)
+2.00%+10.22%+36.29%-76.37% 107M
-0.27%-0.41%+20.80%+27.69% 12.72B
-0.06%+0.20%+16.64%+27.56% 7B
-1.58%-2.77%+49.66%+30.67% 6.53B
+0.80%-3.02% - - 5.47B
-1.95%+12.88%-10.61%+67.52% 5.14B
+1.69%+1.58%-29.82%-21.10% 3.91B
+1.54%+1.97%+52.14%-2.61% 2.08B
-4.62%+11.96%-16.11%+138.17% 1.87B
-2.91%+2.43%+50.71%-11.59% 1.7B
Average -0.52%+3.69%+18.86%+19.99% 4.65B
Weighted average by Cap. -0.49%+1.37%+17.13%+30.07%

Financials

2026 *2027 *
Net sales 90.55M 77.72M 72.95M 66.62M 126M 8.64B 126M 863M 335M 4.36B 340M 333M 14.43B 98.31M 84.38M 79.2M 72.34M 137M 9.38B 137M 937M 363M 4.73B 369M 361M 15.67B
Net income -44.24M -37.97M -35.64M -32.55M -61.43M -4.22B -61.72M -422M -163M -2.13B -166M -162M -7.05B -40.71M -34.94M -32.8M -29.96M -56.54M -3.88B -56.81M -388M -150M -1.96B -153M -150M -6.49B
Net Debt - -
Logo Pulmonx Corporation
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
Employees
296
Date Price Change Volume
27/08/26 $2.535 +1.40% 56,743
26/08/26 $2.500 0.00% 313,697
25/08/26 $2.500 +9.65% 581,671
24/08/26 $2.280 +0.88% 393,831
21/08/26 $2.260 -1.74% 610,195
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.500USD
Average target price
3.400USD
Spread / Average Target
+36.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LUNG Stock